Acadia Pharmaceuticals Inc. (ACAD)

Last Three Months

23-Aug-24 -- 22-Nov-24

Time Period:

Three Months
|
Year

0 Net Amount

Buy:	0	--
Sell:	0	--

Company Sentiment

Biotechnology

Drugs

Insider Trading Sentiment: Strong Sell

Insider Trading Sentiment: Strong Buy

Sentiment Breakdown by Insider

0

(3)

0

(2)

0

(1)

30

0

4

+1

0

+2

0

+3

Two Year Chart

23-Nov-22 -- 22-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Buy & Sell Volume ($)

Two Year Insider Trading Volume Chart

Recent Insider Trades

Last Transaction		Last Three Months
SEC Filing	Transaction	Insider	Sentiment	Company	Holdings Change	Buy Amount	Sell Amount	Buy Price Range	Sell Price Range
19-Nov-24 8:41 PM View:	19-Nov-24 Planned Option Sale ($68.47K)	Kihara James Principal Accounting Officer		Acadia Pharmaceuticals Inc. - ACAD	24% 16.01K to 19.86K	0	0	--	--	Show Txns Hide Txns

19-Nov-24 8:43 PM View:	19-Nov-24 Planned Option Sale ($173.63K)	Teehan Brendan EVP, COO, Head of Commercial		Acadia Pharmaceuticals Inc. - ACAD	18% 52.61K to 62.1K	0	0	--	--	Show Txns Hide Txns

19-Nov-24 8:40 PM View:	19-Nov-24 Planned Option Sale ($172.45K)	Schneyer Mark C. EVP, Chief Financial Officer		Acadia Pharmaceuticals Inc. - ACAD	22% 43.73K to 53.3K	0	0	--	--	Show Txns Hide Txns

15-Oct-24 6:05 PM View:	12-Oct-24 Option Exercise 0	Ndu Adora Director		Acadia Pharmaceuticals Inc. - ACAD	40% 11.03K to 15.41K	0	0	--	--	Show Txns Hide Txns